Edition:
United Kingdom

Impax Laboratories Inc (IPXL.OQ)

IPXL.OQ on NASDAQ Stock Exchange Global Select Market

17.85USD
13 Dec 2017
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$17.85
Open
$17.90
Day's High
$18.15
Day's Low
$17.45
Volume
327,650
Avg. Vol
340,038
52-wk High
$25.70
52-wk Low
$7.80

Summary

Name Age Since Current Position

Robert Burr

66 Independent Chairman of the Board

Paul Bisaro

56 2017 President, Chief Executive Officer, Director

Bryan Reasons

49 2012 Chief Financial Officer, Senior Vice President - Finance

Douglas Boothe

53 2016 President - Generics Division

Michael Nestor

64 2008 President - Impax Specialty Pharmaceutical Division

Mark Schlossberg

56 2011 Senior Vice President, General Counsel, Corporate Secretary

Jeffrey Nornhold

51 2014 Senior Vice President - Technical Operations

J. Kevin Buchi

61 2017 Director

Janet Vergis

52 2015 Director

Leslie Benet

79 2001 Independent Director

Allen Chao

71 2010 Independent Director

Mary Pendergast

66 2013 Independent Director

Peter Terreri

59 2003 Independent Director

Biographies

Name Description

Robert Burr

Mr. Robert L. Burr is Independent Chairman of the Board of Impax Laboratories Inc. He has been a self-employed investment manager since May 2008. Mr. Burr was employed by J.P. Morgan Chase & Co. and associated entities from 1995 to May 2008, at which time he resigned his position as Managing Partner of the Fleming US Discovery III Funds. From October 2001 to October 2005, Mr. Burr was also a Partner at Windcrest Discovery Investments LLC, an investment management firm. From 1992 to 1995, Mr. Burr was head of Private Equity at the investment banking firm Kidder, Peabody & Co. Inc. Prior to that time, Mr. Burr served as the Managing General Partner of Morgan Stanley Ventures and General Partner of Morgan Stanley Venture Capital Fund I, L.P. and was a corporate lending officer with Citibank, N.A. Mr. Burr received an MBA from Columbia University and a BA from Stanford University.

Paul Bisaro

Mr. Paul M. Bisaro is President, Chief Executive Officer, Director of the company. Prior to joining Watson in 2007, Mr. Bisaro was President, Chief Operating Officer and a member of the Board of Directors of Barr Pharmaceuticals, Inc. a global specialty pharmaceutical company (Barr), from 1999 to 2007. Between 1992 and 1999, Mr. Bisaro served as General Counsel of Barr, and from 1997 to 1999, served in various additional capacities. Prior to joining Barr, he was associated with the law firm Winston & Strawn and a predecessor firm, Bishop, Cook, Purcell and Reynolds, from 1989 to 1992. He also served as a Senior Consultant with Arthur Andersen & Co. Mr. Bisaro currently serves on the board of directors of Allergan, Zoetis, Inc. and on the Board of Visitors ofthe Catholic University of America'sColumbus Schoolof Law. Mr. Bisaro also serves on the Board of Zimmer Biomet Holdings, Inc. but has notified the board that he will not stand for re-election as a director at the company's 2017 annual meeting of stockholders. He also served as Chairman of the Board of the Generic Pharmaceutical Association (GPhA) in 2010 and 2011.

Bryan Reasons

Mr. Bryan M. Reasons is Chief Financial Officer, Senior Vice President - Finance of Impax Laboratories, Inc. He has served as our Senior Vice President, Finance and Chief Financial Officer since December 2012 and previously served as our Acting Chief Financial Officer from June 2012 to December 2012 and as our Vice President, Finance from January 2012 to June 2012. Since March 2017, Mr. Reasons has served on the board of directors and on the audit committee of Recro Pharma, Inc. (NASDAQ: REPH), a specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of acute post-operative pain. Prior to joining us in January 2012, Mr. Reasons served as Vice President, Finance, from January 2010 to November 2011 and as Vice President, Risk Management and General Auditor, from October 2005 to January 2010 at Cephalon, Inc. (“Cephalon”), a biopharmaceutical company. Following the acquisition of Cephalon by Teva Pharmaceutical Industries Ltd., a generic pharmaceuticals company, he served as Vice President, Finance of Teva from November 2011 to January 2012. Prior to joining Cephalon, Mr. Reasons held various finance management positions at DuPont from 2003 to 2005 and served as senior manager at PricewaterhouseCoopers LLP from 1992 to 2003. Mr. Reasons has a Bachelor’s Degree in accounting from Pennsylvania State University and an MBA from Widener University and is a certified public accountant.

Douglas Boothe

Mr. Douglas S. Boothe has been appointed as President - Generics Division of the Company effective August 1, 2016. Mr. Boothe has served as Executive Vice President and General Manager, Rx Pharmaceuticals of Perrigo Company plc (“Perrigo”), a publicly traded global over-the-counter consumer goods and pharmaceutical company, since January 2013. Prior to joining Perrigo, Mr. Boothe served as Chief Executive Officer of Actavis, Inc. (“Actavis”) from August 2008 to December 2012 and as its Executive Vice President and Chief Operating Officer from 2006 to 2008. Prior to such time, Mr. Boothe held various senior positions in strategic planning and business development at Alpharma Inc. (subsequently acquired by Actavis) and Pharmacia Corporation (subsequently acquired by Pfizer Inc.). Mr. Boothe holds a BSE in Mechanical & Aerospace Engineering from Princeton University and an MBA from the University of Pennsylvania's Wharton School of Business.

Michael Nestor

Mr. Michael J. Nestor is President - Impax Specialty Pharmaceutical Division of Impax Laboratories Inc. Before joining us, he has served as President of our branded products division, Impax Specialty Pharma, since March 2008. Before joining us, he was Chief Operating Officer of Piedmont Pharmaceuticals, a specialty pharmaceutical company, from July 2007 to March 2008. Prior to Piedmont, Mr. Nestor was CEO of NanoBio, a startup biopharmaceutical company from December 2004 to November 2006, prior to which he was employed by Alpharma, initially as President of its generic pharmaceutical business and later as President of its branded pharmaceutical business. Before Alpharma, he was President, International business at Banner Inc. a global contract manufacturing concern. Prior to Banner, Mr. Nestor spent 16 years at Lederle Laboratories / Wyeth holding increasing positions of responsibility including Vice President, Cardiovascular business, Vice President / General Manager of Lederle-Praxis Biologics, and Vice President of Wyeth-Lederle Vaccines and Pediatrics. Mr. Nestor has a Bachelor of Business Administration degree from Middle Tennessee State University and an MBA from Pepperdine University.

Mark Schlossberg

Mr. Mark A. Schlossberg Esq is Senior Vice President, General Counsel, Corporate Secretary of Impax Laboratories Inc. He has served as our Senior Vice President, General Counsel and Corporate Secretary since May 2011. Since September 2015, he has served on the board of directors of Immunocelluar Therapeutics Ltd (NYSE: IMUC), a clinical-stage company focused on the development of immune-based therapies for the treatment of brain and other cancers based in Los Angeles, California. Prior to joining us, he served as Vice President, Associate General Counsel of Amgen Inc. human therapeutics biotechnology company, from September 2004 to May 2011. Prior to joining Amgen, he held legal and business positions at Medtronic, Inc. a medical technology company and legal positions at Diageo plc, RJR Nabisco, Inc. and Mudge Rose Guthrie Alexander & Ferdon. He earned a Bachelor of Sciences in business administration, finance from the University of Southern California and a Juris Doctor degree from Emory University.

Jeffrey Nornhold

Mr. Jeffrey D. Nornhold is Senior Vice President, Technical Operations of Impax Laboratories Inc. He has served as our Senior Vice President of Technical Operations since April 2014 and is responsible for the Company's manufacturing, supply chain, quality and technical operations. Previously, Jeff served as our Senior Vice President, Global Quality Affairs from March 2011 to April 2014 and was responsible for establishing the foundation for a sustainable quality and compliance program. Jeff joined us from Watson Pharmaceuticals, Inc. (now Actavis plc) where he was the Vice President, Quality Operations – International from March 2010 to March 2011 and was responsible for outside of the U.S. manufacturing sites for both dosage and active pharmaceutical ingredients. While at Watson, he also served as Vice President, U.S. Quality Operations leading the development and execution of quality initiatives for all U.S. sites from February 2007 to March 2010. Prior to joining Watson in 2000, he held numerous leadership positions within the pharmaceuticals industry. He earned a Bachelor of Science degree in chemistry from Bowling Green State University and a Master's in Business Administration from the University of Southern California Marshall School of Business.

J. Kevin Buchi

Mr. J. Kevin Buchi is Director of TetraLogic Pharmaceuticals Corporation. Prior to such time, Mr. Buchi served as our Interim President and Chief Executive Officer from December 19, 2016 until March 27, 2017. From August 2013 to December 2016, Mr. Buchi served as President and Chief Executive Officer and a member of the board of directors of TetraLogic Pharmaceuticals Corporation (formerly NASDAQ: TLOG), a clinical-stage biopharmaceutical company (“TetraLogic Pharmaceuticals”), which assets were subsequently acquired by Medivir AB in December 2016. Prior to his time at TetraLogic Pharmaceuticals, Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a pharmaceutical company (“Teva”), from October 2011 to May 2012. Prior to his position at Teva, Mr. Buchi served as Chief Executive Officer of Cephalon, Inc. (formerly NASDAQ: CEPH), a pharmaceutical company subsequently acquired by Teva (“Cephalon”), from December 2010 to October 2011, and held various positions at Cephalon including Chief Operating Officer from January 2010 to December 2010 and Chief Financial Officer from 1996 to 2009. Since April 2013, he has served as a director on the board and as a member of the remuneration and nominating committee and audit committee of the board of Benitec Biopharma Ltd. (NASDAQ: BNTC), a biotechnology company headquartered in Australia. Mr. Buchi received his B.A. degree from Cornell University and a Masters of Management from the J.L. Kellogg Graduate School of Management at Northwestern University.

Janet Vergis

Ms. Janet S. Vergis is Director of Impax Laboratories, Inc. currently serves as Executive Advisor to Water Street HealthCare Partners, LLC, a private equity firm specializing in strategic investments in healthcare companies, where she has been retained since January 2015, and as Executive Advisor to Deerfield Management, an investment company focused on providing financing alternatives to healthcare companies, where she has been retained since July 2015. Ms. Vergis previously served as an advisor to Warburg Pincus, LLC, a private equity firm, from January 2013 to December 2014 and as Chief Executive Officer of OraPharma, Inc. (“OraPharma”), a specialty pharmaceutical company dedicated to oral health, from January 2011 to August 2012. Prior to joining OraPharma, Ms. Vergis served as founder of Nulatis Therapeutics, Inc., a privately held neuroscience company, from January 2010 to September 2010 and as President of three United States subsidiary companies of Johnson & Johnson, a New York Stock Exchange listed health care company, from 2004 until 2009. Since May 2014, Ms. Vergis has served as a director on the board of directors and a member of the audit committee of Church & Dwight Co., Inc., a New York Stock Exchange listed consumer goods company. She previously also served as a director of Lumara Health, a privately held pharmaceutical company, from October 2013 to November 2014 and as a director of OraPharma from January 2011 to June 2012. Ms. Vergis received her M.S. degree in Physiology and her B.S. degree in Biology from The Pennsylvania State University.

Leslie Benet

Dr. Leslie Z. Benet, Ph.D. is Independent Director of Impax Laboratories Inc. He has been a Professor since 1969 of, and has also served as Chairman of, the Department of Bioengineering and Therapeutic Sciences (1978-1998), University of California, San Francisco (UCSF). Dr. Benet has been a founder of four biopharmaceutical start-up companies, for one of which he presently serves as chair of the Scientific Advisory Board (Hurel Corp). He received his A.B. (English), B.S. (Pharmacy), and M.S. from the University of Michigan, and his Ph.D. from the University of California. Dr. Benet has received nine honorary doctorates: Uppsala University, Sweden (Pharm.D. 1987); Leiden University, The Netherlands (Ph.D. 1995); University of Illinois at Chicago (D.Sc. 1997); Philadelphia College of Pharmacy and Science (D.Sc. 1997); Long Island University (D.Sc. 1999); University of Athens, Greece (Ph.D. 2005); Catholic University of Leuven, Belgium (Ph.D. 2010), University of Michigan (D.Sc. 2011) and University of Lisbon, Portugal (Ph.D. 2016). In 1985, Dr. Benet served as President of the APhA Academy of Pharmaceutical Sciences. During 1986, Dr. Benet was a founder and first President of the American Association of Pharmaceutical Scientists. In 1987, Dr. Benet was elected to membership in the National Academy of Medicine (formerly the Institute of Medicine, IOM). Dr. Benet formerly served as Chair of the FDA Expert Panel on Individual Bioequivalence and the FDA Center for Biologics Peer Review Committee, and as a member of the FDA Science Board and the Generic Drugs Advisory Committee. From 2005 through 2012, Dr. Benet served as a member of the IOM Forum on Drug Discovery, Development and Translation.

Allen Chao

Dr. Allen Chao, Ph.D. is Independent Director of Impax Laboratories Inc. He has been Chairman of Newport Healthcare Advisors, LLC, a healthcare investment management and consulting company, since January 2008 and since December 2014, has served as Chief Executive Officer of Tanvex BioPharma, Inc. a Taiwan-based company listed on the Emerging Stock Board of the Taipei Exchange principally engaged in the research, development and manufacture of biosimilars. Dr. Chao was a co-founder of Watson Pharmaceuticals, Inc. (now Allergan plc (NYSE: AGN)), a specialty pharmaceutical company, serving as a director from 1985 to May 2008, Chairman of the board of directors from May 1996 to May 2008, and Chief Executive Officer from 1985 to September 2007. While at Watson, Dr. Chao oversaw the company’s growth, through internal R&D, licensing and acquisitions of pharmaceutical products and technologies, as well as mergers and acquisition activities. Dr. Chao received a Ph.D. in industrial and physical pharmacy from Purdue University in 1973. In May 2000, he received the degree of Doctor of Science from Purdue.

Mary Pendergast

Ms. Mary K. Pendergast, J.D. is Independent Director of Impax Laboratories, Inc. effective July 3, 2013. Ms. Pendergast has been President and founder of Pendergast Consulting, a legal and regulatory consulting firm to pharmaceutical and biotechnology companies since 2003, where she focuses on both strategic and tactical issues relating to drug policy and development. From 1998 to 2003, Ms. Pendergast served as Executive Vice President, Government Affairs, at Elan Corporation plc (“Elan”), a biotechnology company headquartered in Ireland, where she was responsible for creating the government affairs and corporate compliance offices and supporting the corporate compliance office at the company. Prior to joining Elan, Ms. Pendergast served as Deputy Commissioner and Senior Advisor to the Commissioner at the FDA from 1990 to 1997, and as Associate Chief Counsel for Enforcement at the FDA from 1979 to 1990. Ms. Pendergast currently serves on the board of directors of ICON plc, a NASDAQ listed global provider of outsourced development services to pharmaceutical, biotechnology and medical device industries. She previously served on the board of directors of ARCA biopharma, Inc., a NASDAQ listed biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, from 2002 until 2011. She received her LL.M. from Yale Law School, her J.D. degree from the University of Iowa College of Law, and her B.A. from Northwestern University.

Peter Terreri

Mr. Peter R. Terreri CPA. is Independent Director of Impax Laboratories Inc. He is President, Chief Executive Officer and director of CGM, Inc. a manufacturing company that he has owned and operated since 2000. He previously served as Senior Vice President and Chief Financial Officer of Teva Pharmaceuticals USA from 1985 through 2000 and as an auditor at PricewaterhouseCoopers LLP from 1981 to 1984. Mr. Terreri received his B.S. in Accounting from Drexel University and has been a certified public accountant since 1981.

Basic Compensation

Name Fiscal Year Total

Robert Burr

389,374

Paul Bisaro

--

Bryan Reasons

2,248,520

Douglas Boothe

2,499,380

Michael Nestor

2,000,560

Mark Schlossberg

1,991,480

Jeffrey Nornhold

2,578,390

J. Kevin Buchi

234,555

Janet Vergis

318,541

Leslie Benet

344,374

Allen Chao

349,374

Mary Pendergast

364,374

Peter Terreri

356,874
As Of  31 Dec 2016